13 nəticələr
FIELD OF THE INVENTION
The present invention relates to the general fields of pharmaceuticals and cancer chemotherapy, particularly to the areas of cytotoxic antitumor agents and DNA intercalating agents. The invention also relates to medicinal chemistry, and the fields of acridone and
The present application is a U.S. National Phase (371 application) of PCT/GB01/03046, filed 6 Jul. 2001.
TECHNICAL FIELD
This invention pertains generally to the field of telomerase inhibitors and antiproliferative agents, and more specifically to certain acridone and acridine compounds which
TECHNICAL FIELD
This invention pertains generally to the field of chemistry and pharmaceuticals, and more specifically to certain acridine and acridine compounds which inhibit telomerase, regulate cell proliferation, etc., and/or treat cancer, proliferative conditions, etc. The present invention
TECHNICAL FIELD
This invention pertains generally to the field of telomerase inhibitors and antiproliferative agents, and more specifically to certain acridone and acridine compounds which inhibit telomerase and/or regulate cell proliferation. The present invention also pertains to pharmaceutical
FIELD OF THE INVENTION
The present invention broadly relates to compositions comprising hepatic therapeutic actives comprising one or more acridone compounds, one or more xanthone compounds, one or more thioxanthone compounds, one or more tocotrienol compounds, and one or more oleanolic triterpenoid
FIELD OF THE INVENTION
The present invention broadly relates to compositions comprising hepatic therapeutic actives comprising one or more acridone compounds, one or more xanthone compounds, one or more thioxanthone compounds, one or more tocotrienol compounds, and one or more oleanolic triterpenoid
FIELD OF THE INVENTION
The present invention broadly relates to compositions comprising hepatic therapeutic actives comprising one or more acridone compounds, one or more xanthone compounds, one or more thioxanthone compounds, one or more tocotrienol compounds, and one or more oleanolic triterpenoid
FIELD OF THE INVENTION
The present invention relates to acridone-derived compounds which are bisimidazoacridones, bistriazoloacridones and hybrid molecules having both imidazoacridone and triazoloacridone moieties. These compounds are useful as anti-neoplastic and anti-retroviral agents.
BACKGROUND
FIELD OF THE INVENTION
The present invention relates to acridone-derived compounds which are bisimidazoacridones, bistriazoloacridones and hybrid molecules having both imidazoacridone and triazoloacridone moieties. These compounds are useful as anti-neoplastic and anti-retroviral agents.
BACKGROUND
FIELD OF THE INVENTION
The present invention concerns compounds that inhibit cyclin-dependent kinases, particularly the cyclin-dependent kinase CDK4, and methods for treating cancers using such compounds.
BACKGROUND OF THE INVENTION
Physiology
In a normal cell CDK4:cyclin D kinase holoenzyme
The invention described herein was made in the course of work under Grant Nos. CA08748 and CA18856 from the National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. The U.S. Government has certain rights in this invention.
BACKGROUND OF THE
BACKGROUND OF THE INVENTION
1. Technical Field of the Invention
The invention relates to a process for the preparation of (5-[[.omega.-(dialkylamino)alkyl]amino]-8-hydroxyimidazo[4,5,1-de]acridin- 6-ones of general formula (I), ##STR3##
wherein R.sup.1 and R.sup.2 represent alkyl groups of 1 to 4
FIELD OF THE INVENTION
The present invention relates to novel dye-sulfenate compounds, and to phototherapeutic procedures using these compounds.
BACKGROUND OF THE INVENTION
The use of visible and near-infrared (NIR) light in clinical practice is growing rapidly. Compounds absorbing or emitting in